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Introduction
As in previous years, this has become one of the key meet-
ings of the year for both scientists and clinicians who are
involved in breast cancer, and in particular provides a forum
in which to discuss the more translational aspects of current
research. This year was no exception, and there was much
enthusiasm among those interested in endocrine aspects
about new clinical and preclinical data regarding several
novel agents, including pure antioestrogens, aromatase
inhibitors and selective oestrogen receptor modulators
(SERMs), as well as continuing studies to elucidate the mol-
ecular biology of oestrogen receptor (ER) function.
Pure antioestrogens for tamoxifen-resistant
advanced breast cancer
The fact that clinical responses are seen with second-line
endocrine therapy in ER-positive breast cancer after the
development of resistance to tamoxifen implies that some
tumours retain partial hormone sensitivity. Several years
ago, considerable interest was generated by a small
phase II study that suggested substantial activity in tamox-
ifen-resistant breast cancer with the pure steroidal anti-
oestrogen ICI 182,780, which was devoid of any intrinsic
agonist activity. This observation was supported by experi-
mental data in MCF-7 ‘tamoxifen-resistant’ xenografts,
which confirmed that ICI 182,780, but not the structurally
related triphenylethylene toremiphene, could inhibit the
growth of resistant tumours.
These observations prompted two large randomized
phase III trials to be initiated in women with advanced
tamoxifen-resistant breast cancer that compared ICI
182,780 (Faslodex; AstraZeneca, Macclesfield, UK) with
anastrozole, and the first data from these trials were
reported at the San Antonio meeting. Both trials demon-
strated that the clinical efficacy of Faslodex was identical
to that of anastrozole in tamoxifen-resistant advanced
breast cancer with respect to the primary end-point,
namely time to disease progression. In the European trial
reported by Howell (Christie Hospital, Manchester, UK)
the response rate to Faslodex was 20.7% versus 15.7%
for anastrozole, with an additional 23.9 and 29.3%
patients, respectively, deriving clinical benefit as deter-
mined by stable disease for at least 6 months. In the Amer-
ican study reported by Osborne (Baylor College of
Medicine, Houston, TX, USA), which unlike the European
study was a double-blind design with a slightly greater
number of patients who were known to be ER-positive, the
response rates were 17.5% for both arms. Interestingly,
there was a nonsignificant trend towards a longer duration
of response for Faslodex (median 19.3 versus
10.5 months), and an additional 24.8 and 18.6% of
patients, respectively, had stable disease for 6 months.
The toxicity profiles were similar in terms of endocrine
effects, and in the double-blind US study the incidence of
injection site reactions was identical in the Faslodex and
placebo arms of the trial.
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These data therefore confirm that a pure steroidal anti-
oestrogen is active in tamoxifen-resistant breast cancer,
and in these two randomized trials is at least as effective
as a third-generation aromatase inhibitor, a drug class that
has become the standard of care. The real issue is at what
point in the sequence of endocrine therapy options for
advanced breast cancer should a pure antiestrogen be
used. With the potential for incorporation of aromatase
inhibitors as first-line therapy, it will become important to
determine whether pure antioestrogens are active after
failure of aromatase inhibitors. Data were presented by
Thurliman (SAKK, St Galen, Switzerland) that confirm that
responses to tamoxifen may be still be seen after anastro-
zole treatment, and small phase II studies are in progress
with Faslodex in this scenario to determine the optimal
sequence of therapies.
Aromatase inhibitors are superior to
tamoxifen as first-line therapy
Data were presented, on behalf of the International Letro-
zole Study Group, from the largest prospective single
study of an aromatase inhibitor versus tamoxifen as first-
line therapy in advanced breast cancer. Letrozole was
associated not only with a higher response rate than was
tamoxifen (30% versus 20%; P = 0.0006), but also with a
significantly longer time to disease progression
(9.4 months versus 6 months; P = 0.0001). The improved
likelihood of benefit was seen in all subgroups. Likewise,
Paridaens (EORTC, Leuven, Belgium) presented a smaller
randomized phase II first-line study conducted by the
European Organization for Research in Cancer Therapy, in
which the response rate to the steroidal aromatase
inhibitor exemestane was substantially higher than that to
tamoxifen (45% versus 14%). A larger randomized phase
III study is underway on the basis of these promising data.
Thus, there are now published data for all of the third-gen-
eration aromatase inhibitors (anastrozole, letrozole and
exemestane) that indicate that these drugs may be supe-
rior to tamoxifen as first-line therapy in ER-positive post-
menopausal advanced breast cancer.
The aromatase inhibitor letrozole also appears to be more
effective than tamoxifen when given as 4-month preopera-
tive (neoadjuvant) therapy to 337 postmenopausal women
with ER-positive and/or progesterone receptor-positive,
large operable or locally advanced breast cancer. This
was manifest both as an improved response rate (55%
versus 36%; P < 0.001) and as an increase in the ability
to perform breast-conserving surgery. Ellis (Duke Univer-
sity, Durham, NC, USA) presented data that tumours that
coexpressed HER-2 (<15%) were found to be much more
likely to respond to letrozole and tamoxifen. Hitherto it has
been assumed that ER-positive, HER-2-positive breast
cancers are endocrine resistant, but these interesting data
imply that this may differ depending on the endocrine ther-
apeutic approach.
New selective estrogen receptor modulators
It has already been shown that the SERM raloxifene signif-
icantly reduced the incidence of breast cancer in a post-
menopausal osteoporosis population of women. In an
update of this study of over 7700 women by Lippman
(Lombardi Cancer Center, Georgetown, Washington, DC,
USA), data were presented that indicate that the greatest
risk reduction by raloxifene may be seen in those women
with the higher lifetime exposure to oestrogen as indicated
by surrogate end-points such as bone mineral density,
body mass index and serum oestradiol levels. The updated
data confirm that, unlike tamoxifen, raloxifene was not
associated with any increase in risk of endometrial cancer
(relative risk 0.91), although the relative risk of thrombotic
events remains a concern. The current STAR chemopre-
vention trial comparing the effects of tamoxifen with ralox-
ifene will hopefully characterize further those patients who
derive most benefit from chemoprevention, and define
further the risk–benefit for each intervention.
Preclinical data were presented on several other SERM
compounds that are in early clinical development.
LY 353381 (Arzoxifene; Eli Lilly, Indianapolis, IN, USA) is a
benzothiophene analogue that is similar, but not identical
to raloxifene. Although this agent has been shown to have
antioestrogenic effects on the rat uterus, data were pre-
sented by Dardes (Northwestern University Medical
School, Chicago, IL, USA) that showed that, in an
endometrial cancer model in athymic mice, similar growth
stimulatory effects were seen as compared with tamoxifen.
In contrast, ERA-923 is a novel SERM that appears to
have an improved preclinical profile as compared with
tamoxifen and raloxifene. Greenberger (Wyeth-Ayerst
Research, Radnor, PA, USA) presented data that not only
was ERA-923 devoid of agonist effects in an immature rat
uterotrophic model and failed to stimulate EnCa101
endometrial xenografts in vivo, but it also lacked any stim-
ulatory effect and inhibited the growth of tamoxifen-resis-
tant MCF-7 breast cancer xenografts. On the basis of
these data, the drug is currently being evaluated in clinical
trials in women in whom tamoxifen treatment has failed.
EM-652 is a prodrug of EM-800, a SERM that has also
been investigated in tamoxifen-resistant breast cancer.
Data were presented by Johnston (Royal Marsden Hospi-
tal and Institute of Cancer Research, London, UK) that
demonstrated that EM-652, unlike raloxifene, is a more
potent antioestrogen that is totally devoid of any agonist
effects in the immature rat uterotrophic assay. Likewise,
data were presented by Martel (Laval University Medical
Centre, Quebec, QC, Canada) that showed that EM-652
is a nonsteroidal compound that appears to be a pure
antioestrogen in human endometrial adenocarcinoma
cells, and behaves differently from other SERMs such as
raloxifene and lasofoxifene. Other triphenylethylene struc-
tures related to tamoxifen continue to be investigated,Breast Cancer Research    Vol 3 No 3 Johnston
including compounds such lasofoxifene and GW-7604.
Data were presented by Bentram (Northwestern University
Medical School, Chicago, IL, USA) with the latter com-
pound, which appears to have lesser agonist properties
that tamoxifen in specific preclinical models. However, it
remains unclear to what extent these preclinical models
are in any way predictive of clinical outcome in the treat-
ment of breast cancer.
Understanding the molecular biology of
oestrogen receptor
A special minisymposium was dedicated to reviewing the
latest aspects of ER structure and function. The emerging
biology of ER-b, together with its contrasting effects to
those of ER-a, was discussed by Gustaffson (Karolinska
Instutet, Stockholm, Sweden). Experiments with ER-b-
knockout mice have demonstrated that, in the uterus, cell
proliferation is markedly enhanced, implying that ER-b may
have some form of balancing role. ER-b levels may fluctu-
ate during physiological breast development and lactation,
and ongoing studies in human breast carcinomas may
determine the role of levels of ER-b relative to those of ER-
a in determining clinical outcome to endocrine therapy.
The complexity of the structure–function relationship
between ER and its various ligands was reviewed by
Greene (University of Chicago, Chicago, IL, USA), and
may explain some aspects of the different outcomes,
which depend on which ligands interact with the receptor.
After ligand binding there appear to be a multiplicity of
ligand-induced surfaces that act as docking sites for coac-
tivators and corepressors. Structural differences between
ER-a and ER-b may explain agonist versus antagonist
responses to the same ligand, although the full interaction
between the AF-1 and AF-2 transactivation sites is not yet
fully understood. The possibility exists, on the basis of
crystallographical modelling, that small-molecule mimetics
could be synthesized to inhibit key protein–protein interac-
tions that are crucial to liganded ER function. The molecu-
lar pharmacology of the different SERMs was reviewed by
McDonnell (Duke University, Durham, NC, USA), and
these effects may also be explained by different struc-
ture–function relationships of each compound with ER.
For example, GW-5638, which inhibits the growth of
tamoxifen-resistant tumours in oophorectomized mice,
induces a different conformational shape with ER com-
pared with tamoxifen, and as such prevents a novel coacti-
vator (CoAabV) from binding to ER.
The concept is emerging that ER may exist in one of three
active states: repressor, neutral or coactivator. As such, one
factor that may dictate the response to a given ligand is the
relative levels of corepressor and coactivator proteins.
Experimental data suggest that overexpression of corepres-
sors may convert all SERMs into agonists in a given cell
system, thus confirming that cell context in addition to
receptor isotype and ligand may determine the biological
response. Likewise, mutations in critical domains of ER
may alter the response. Jordan (Lurie Comprehensive
Cancer Center, Northwestern University, Chicago, IL,
USA) presented data with a mutated ER (D351Y) isolated
from a tamoxifen-stimulated tumour line, in which the
amino acid involved appeared critical for interaction with a
ligand’s side chain. Although ER mutations may be rela-
tively rare, any change in structure at crucial sites may dra-
matically alter the biological response to individual ligands.
Conclusion
The emergence into the clinic of several novel endocrine
therapies has given clinicians new options in the manage-
ment of breast cancer, although the correct sequence of
treatment still needs to be established. There is little doubt
that, in time, tamoxifen will be replaced by more specific
targeted therapies, and that the profile of the current
SERMs is of considerable interest for early-stage disease
and possibly prevention. At the same time, our understand-
ing of oestrogen receptor biology and the consequence of
ligand interaction in different tissues is expanding, which
should allow us to maximize the properties of these various
new endocrine agents which are now available.